<DOC>
	<DOC>NCT00927875</DOC>
	<brief_summary>The purpose of this study is to determine the maximum tolerated dose (MTD) of BMS-833923 administered in combination with carboplatin and etoposide followed by BMS-833923 alone in subjects with extensive-stage Small Cell Lung Cancer (SCLC).</brief_summary>
	<brief_title>A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Histologically or cytologically confirmed small cell lung cancer, without prior chemotherapy treatment Men and Women at least 18 years old Eastern Cooperative Oncology Group (ECOG) status 02 Significant cardiovascular disease Prior treatment of small cell lung cancer is not permitted, except for palliative radiation to a limited field excluding the chest (e.g. for painful metastasis). Symptomatic brain metastases Women pregnant or breastfeeding Women of childbearing potential (WOCBP) unwilling/unable to use acceptable method to avoid pregnancy Uncontrolled medical disorder or active infection Concurrent therapy with any other investigational product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>